CURI(CURI)
CURI
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E |
|---|---|---|---|
| Revenue Avg | $78M | $88M | $97M |
| Low | $78M | $88M | $95M |
| High | $78M | $89M | $98M |
| EBITDA Avg | $-7M | $-8M | $-9M |
| Low | $-7M | $-8M | $-9M |
| High | $-7M | $-8M | $-9M |
| EBIT Avg | $-37M | $-42M | $-46M |
| Low | $-37M | $-42M | $-46M |
| High | $-37M | $-41M | $-45M |
| Net Income Avg | $6M | $10M | $20M |
| Low | $2M | $9M | $20M |
| High | $7M | $11M | $21M |
| EPS Avg | $0.08 | $0.17 | $0.35 |
| Low | $0.04 | $0.15 | $0.34 |
| High | $0.13 | $0.19 | $0.36 |
| Analysts (Rev / EPS) | 2 / 2 | 2 / 2 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|
| Revenue Avg | $20M | $21M | $18M | $23M | $22M | $24M |
| Low | $20M | $21M | $18M | $22M | $22M | $23M |
| High | $20M | $22M | $18M | $23M | $22M | $24M |
| EBITDA Avg | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M |
| Low | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M |
| High | $-2M | $-2M | $-2M | $-2M | $-2M | $-2M |
| EBIT Avg | $-9M | $-10M | $-9M | $-11M | $-10M | $-11M |
| Low | $-9M | $-10M | $-9M | $-11M | $-11M | $-11M |
| High | $-9M | $-10M | $-8M | $-11M | $-10M | $-11M |
| Net Income Avg | $1M | $3M | $2M | $3M | $3M | $4M |
| Low | $491,241 | $3M | $2M | $3M | $3M | $3M |
| High | $2M | $3M | $2M | $3M | $3M | $4M |
| EPS Avg | $0.03 | $0.04 | $0.03 | $0.05 | $0.05 | $0.06 |
| Low | $0.01 | $0.04 | $0.03 | $0.05 | $0.05 | $0.06 |
| High | $0.03 | $0.05 | $0.03 | $0.05 | $0.05 | $0.06 |
| Analysts (Rev / EPS) | 2 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |